Lung cancer: The immune system and radiation

British Journal of Biomedical Science

Volumn 72, Issue 2, 2015, Pages 78-84

  Mendes, F ^a,b,c   Antunes, C ^b   Abrantes, A M ^a,c   Goncalves A C ^c,d   Nobre Gois, I ^e   Sarmento, A B ^c,e   Botelho, M F ^a,c   Rosa, M S ^d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b POLYTECHNIC INSTITUTE OF COIMBRA   (Portugal)

^c Inst of Pharmacol and Therapeutics   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Carcinoma, non small cell lung; Immune system; Lung neoplasms; Radiotherapy; Small cell lung carcinoma

Indexed keywords

CYTOKINE; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORRELATION ANALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; REVIEW; SMALL CELL LUNG CANCER; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; LUNG NEOPLASMS; RADIATION RESPONSE;

HUMANS; IMMUNE SYSTEM; LUNG NEOPLASMS;

EID: 84942614118     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2015.11666801     Document Type: Review

References (49)

1. Internation Agency for Researc h on Cancer. Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide. Lyon: IARC, 2014.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (2): 11-30.
3. Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-smallcell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer 2013; 79 (3): 193-7.
4. Barnard S. Lung cancer: epidemiology, treatment. Surgery 2004; 22 (5): 97-100.
5. Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123 (1 Suppl): 157S-166S.
6. Stewart DJ ed. Lung cancer: prevention, management and emerging therapies. Chichester: Humana, 2010.
7. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996; 52 (1): 12-21.
8. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83 (5): 584-94.
9. Goldstraw P, Ball D, Jett JR et al. Non-small-cell lung cancer. Lancet 2011; 378 (9804): 1727-40.
10. Wistuba II, Gazdar a F. Molecular pathology of lung cancer. Verh Dtsch Ges Pathol 2000; 84: 96-105.
11. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo a, Genestreti G. Small cell lung cancer. Ann Oncol 2006; 17 (Suppl 2): ii5-10.
12. Saeed I, Anderson J. Cancer of the lung: staging, radiology, surgery. Surgery 2011; 29 (5): 221-6.
13. Bearz A, Berretta M, Lleshi A, Tirelli U. Target therapies in lung cancer. J Biomed Biotechnol 2011; 2011: 921231.
14. Ray M, Jablons D, He B. Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med 2010; 4 (5): 631-45.
15. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363 (18): 1693-703.
16. Cameron SE, Andrade RS, Pambuccian SE. Endobronchial ultrasound-guided transbronchial needle aspiration cytology: a state of the art review. Cytopathology 2010; 21 (1): 6-26.
17. Husain AN, Colby T, Ordonez N et al.; International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013; 137 (5): 647-67.
18. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24 (10): 1348-59.
19. National Comprehensive Cancer Network. Non-small cell lung cancer. NCCN Clinical Practice Guidelines. Fort Washington: NCCN, 2013 (Version 2).
20. Rossi A, Martelli O, Di Maio M. Treatment of patients with smallcell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev 2013; 39 (5): 498-506.
21. Früh M, De Ruysscher D, Popat S et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi99-105.
22. Paumier A, Le Péchoux C. Radiotherapy in small-cell lung cancer: where should it go? Lung Cancer 2010; 69 (2): 133-40.
23. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009; 10 (7): 718-26.
24. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8 (+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61 (10): 3932-6.
25. Ikushima H. Radiation therapy: state of the art and the future. J Med Invest 2010; 57 (1-2): 1-11.
26. Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94 (2): 275-80.
27. de Lima JJ. Biofísica médica 3rd edn (in Portuguese). University of Coimbra: 2014, 873.
28. Maehata Y, Onishi H, Kuriyama K et al. Immune responses following stereotactic body radiotherapy for stage I primary lung cancer. Biomed Res Int 2013; 2013: 731346.
29. Lumniczky K, Sáfrány G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett 2015; 356 (1): 114-25.
30. Joiner M, van der Kogel A eds. Basic clinical radiobiology 4th edn. Boca Raton: CDC, 2009.
31. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010; 15 (4): 411-21.
32. Dienstmann R, Martinez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011; 2 (3): 165-77.
33. Jeremic B ed. Advances in radiation oncology in lung cancer 2nd edn. Heidelberg: Springer-Verlag, 2005.
34. Yuan A, Yu CJ, Chen WJ et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in nonsmall-cell lung cancer. Int J Cancer 2000; 89 (6): 475-83.
35. Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy-association of interleukin-8 and VEGF with survival. Cytokine 2010; 50 (1): 30-6.
36. Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med 2013; 19 (9): 565-82.
37. Chen JJ, Yao P, Yuan A et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003; 9 (2): 729-37.
38. Gridley DS, Bonnet RB, Bush DA et al. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 60 (3): 759-66.
39. Rübe CE, Palm J, Erren M et al. Cytokine plasma levels: reliable predictors for radiation pneumonitis? PLoS One 2008; 3 (8): e2898.
40. Wang J , Qiao XY, Lu FH et al. TGF-beta 1 in serum and induced sputum for predicting radiation pneumonitis in patients with non-small cell lung cancer after radiotherapy. Chin J Cancer 2010; 29 (3): 325-9.
41. Zhao L, Sheldon K, Chen M et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 2008; 59 (2): 232-9.
42. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004; 71 (2): 183-9.
43. Anscher MS. Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 2010; 15 (4): 350-9.
44. Marks LB, Bentzen SM, Deasy JO et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010; 76 (3 Suppl): S70-6.
45. Nakakubo Y, Miyamoto M, Cho Y et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89 (9): 1736-42.
46. Hald SM, Bremnes RM, Al-Shibli K et al. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer 2013; 80 (2): 209-15.
47. Yuan A, Yang PC, Yu CJ et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000; 162 (5): 1957-63.
48. Zhu YM, Bagstaff SM, Woll PJ. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer. Br J Cancer 2006; 94 (12): 1936-41.
49. Xu QY, Gao Y, Liu Y, Yang WZ, Xu XY. Identification of differential gene expression profiles of radioresistant lung cancer cell line established by fractionated ionizing radiation in vitro. Chin Med J (Engl) 2008; 121 (18): 1830-7.